These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 23440574)

  • 1. Pathophysiology and management of thrombosis in cancer: 150 years of progress.
    Soff GA
    J Thromb Thrombolysis; 2013 Apr; 35(3):346-51. PubMed ID: 23440574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of current and emerging antithrombotics in thrombosis and cancer.
    Mousa SA
    Drugs Today (Barc); 2006 May; 42(5):331-50. PubMed ID: 16801996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Thrombosis in spite of warfarin--what should be done?].
    Lassila R
    Duodecim; 2001; 117(24):2632-6. PubMed ID: 12183826
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.
    Meyer G; Marjanovic Z; Valcke J; Lorcerie B; Gruel Y; Solal-Celigny P; Le Maignan C; Extra JM; Cottu P; Farge D
    Arch Intern Med; 2002 Aug 12-26; 162(15):1729-35. PubMed ID: 12153376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is low-molecular-weight heparin safer than warfarin for secondary prevention of venous thromboembolism in cancer patients?
    Caine GJ; Lip GY
    Arch Intern Med; 2003 May; 163(10):1243-4; author reply 1244. PubMed ID: 12767973
    [No Abstract]   [Full Text] [Related]  

  • 6. Considerations and challenges with existing treatments for thrombosis in cancer patients.
    Schwartz RN
    Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S7-9. PubMed ID: 16286367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombosis and cancer: a personal view.
    Donati MB
    Thromb Haemost; 2007 Jul; 98(1):126-8. PubMed ID: 17598003
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of deep vein thrombosis in cancer patients.
    Jahanzeb M
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S50-3. PubMed ID: 16280114
    [No Abstract]   [Full Text] [Related]  

  • 9. Treating thrombosis in the 21st century.
    Shapiro SS
    N Engl J Med; 2003 Oct; 349(18):1762-4. PubMed ID: 14585945
    [No Abstract]   [Full Text] [Related]  

  • 10. The treatment of cancer associated thrombosis: does one size fit all? Who should get LMWH/warfarin/DOACs?
    Noble S; Sui J
    Thromb Res; 2016 Apr; 140 Suppl 1():S154-9. PubMed ID: 27067970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study.
    Lavau-Denes S; Lacroix P; Maubon A; Preux PM; Genet D; Vénat-Bouvet L; Labourey JL; Martin J; Slaouti P; Tubiana-Mathieu N
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):65-73. PubMed ID: 23636449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of cancer-associated thrombosis: distinguishing among antithrombotic agents.
    Pruemer J
    Semin Oncol; 2006 Apr; 33(2 Suppl 4):S26-39; quiz S41-2. PubMed ID: 16638458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apparent warfarin potency inconsistencies compromise effectiveness.
    Rothschild BM
    Arch Intern Med; 2003 May; 163(10):1243; author reply 1244. PubMed ID: 12767972
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of edoxaban vs low-molecular-weight heparin and warfarin for cancer-associated thrombosis in Brazil.
    Lopes DG; Tamayo A; Schipp B; Siepmann T
    Thromb Res; 2020 Dec; 196():4-10. PubMed ID: 32810773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombosis and cancer: 40 years of research.
    Donati MB; Lorenzet R
    Thromb Res; 2012 Mar; 129(3):348-52. PubMed ID: 22264938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
    Nishioka J; Goodin S
    J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer and thrombosis: implications of published guidelines for clinical practice.
    Khorana AA
    Ann Oncol; 2009 Oct; 20(10):1619-30. PubMed ID: 19561038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of DOACs versus LMWH for cancer-associated thrombosis: A systematic review and meta-analysis.
    Tao DL; Olson SR; DeLoughery TG; Shatzel JJ
    Eur J Haematol; 2020 Sep; 105(3):360-362. PubMed ID: 32441350
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical studies with anticoagulants to improve survival in cancer patients.
    Gerotziafas GT; Papageorgiou C; Hatmi M; Samama MM; Elalamy I
    Pathophysiol Haemost Thromb; 2008; 36(3-4):204-11. PubMed ID: 19176993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombosis and Hemostasis in Cancer. Scope of the Problem and Overview.
    Soff G
    Cancer Treat Res; 2019; 179():1-9. PubMed ID: 31317477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.